Literature DB >> 2073584

In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat.

A P Ford1, C A Marsden.   

Abstract

The effects of intracerebral application of neurotensin on the behavioural responses to peripheral dopamine agonist administration to rats, and on the levels of DOPAC voltammetrically determined in the striatum and nucleus accumbens of the anaesthetized rat have been examined. Bilateral application of neurotensin to the nucleus accumbens, like the neuroleptic haloperidol, inhibited the hyperactivity response to the dopamine agonist, n,N-propylnorapomorphine, but, unlike haloperidol, its bilateral intrastriatal application failed to reduce the degree of stereotyped behaviour induced by peripheral apomorphine injection. In the halothane-anaesthetized rat, neurotensin, when applied to the ventral tegmental area, stimulated DOPAC production in the ipsilateral nucleus accumbens, while its application to the substantia nigra did not affect striatal DOPAC levels significantly. Following its intracerebroventricular injection, however, DOPAC levels were considerably enhanced in both regions. The 11-D-tryptophan-substituted analogue of neurotensin potently mimicked the effects of the peptide itself in all studies. The findings of these investigations further confirm in vivo that the functional antagonism of dopamine by neurotensin is selective for the mesolimbic system, and that the effects of neurotensin can be correlated with reports on the regional distribution of its high-affinity binding sites in the rat brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073584     DOI: 10.1016/0006-8993(90)90135-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine.

Authors:  C Betancur; R Cabrera; E R de Kloet; D Pélaprat; W Rostène
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

2.  Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra.

Authors:  H Boudin; D Pélaprat; W Rostène; V M Pickel; A Beaudet
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

3.  Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

Authors:  Yanqi Liang; Mona Boules; Zhimin Li; Katrina Williams; Tomofumi Miura; Alfredo Oliveros; Elliott Richelson
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

4.  Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions.

Authors:  J M Radke; M J Owens; J C Ritchie; C B Nemeroff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

5.  Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference.

Authors:  Klara Felszeghy; José Manuel Espinosa; Hélène Scarna; Anne Bérod; William Rostène; Didier Pélaprat
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

6.  NT79: A novel neurotensin analog with selective behavioral effects.

Authors:  Mona Boules; Yanqi Liang; Siobhan Briody; Tomofumi Miura; Irfan Fauq; Alfredo Oliveros; Mina Wilson; Shaheen Khaniyev; Katrina Williams; Zhimin Li; Yanfei Qi; Michael Katovich; Elliott Richelson
Journal:  Brain Res       Date:  2009-10-27       Impact factor: 3.252

7.  Serotoninergic mechanisms of the effects of neurotensin on passive avoidance behavior in rats.

Authors:  N P Shugalev; A V Stavrovskaya; A S Ol'shanskii; G Hartmann; L Lenard
Journal:  Neurosci Behav Physiol       Date:  2008-07-08

8.  ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse.

Authors:  Larry S Barak; Yushi Bai; Sean Peterson; Tama Evron; Nikhil M Urs; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick R Maloney; Thomas D Y Chung; Ramona M Rodriguiz; William C Wetsel; James B Thomas; Glen R Hanson; Anthony B Pinkerton; Marc G Caron
Journal:  ACS Chem Biol       Date:  2016-05-05       Impact factor: 5.100

9.  The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.

Authors:  James B Thomas; Hernán Navarro; Keith R Warner; Brian Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2009-01-15       Impact factor: 2.823

10.  Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.

Authors:  James B Thomas; Angela M Giddings; Robert W Wiethe; Srinivas Olepu; Keith R Warner; Philippe Sarret; Louis Gendron; Jean-Michel Longpre; Yanan Zhang; Scott P Runyon; Brian P Gilmour
Journal:  J Med Chem       Date:  2014-06-05       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.